Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29851851 | 0.83 | CYP1A2 (0.33) | CYP1A2CYP11B1CYP11B2CYP3A4CYP2C9 | |
| SCHEMBL28875302 | 0.82 | CA1 (0.36) | CYP1A2CYP11B1CYP11B2CYP3A4CYP2C9 | |
| SCHEMBL23364990 | 0.81 | CYP2C9 (0.40) | CYP1A2CYP11B1CYP11B2CYP3A4CYP2C9 | |
| SCHEMBL29113480 | 0.80 | CYP1A2 (0.37) | CYP1A2CYP11B1CYP11B2CYP3A4CYP2C9 | |
| SCHEMBL30612410 | 0.80 | CYP1A2 (0.37) | CYP1A2CYP11B1CYP11B2CYP3A4CYP2C9 | |
| SCHEMBL1895008 | 0.79 | STS (0.33) | CYP3A4STSACHE | |
| SCHEMBL3806985 | 0.78 | PLAU (0.41) | CA1CA2 | |
| SCHEMBL30082721 | 0.74 | CA1 (0.32) | CYP1A2CYP11B1CYP11B2CYP3A4CYP2C9 | |
| SCHEMBL354259 | 0.72 | MTNR1A (0.39) | CA1CA2ACHE | |
| SCHEMBL19603315 | 0.70 | CYP1A2 (0.47) | CYP1A2CYP11B1CYP11B2STSCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278987-A1 | Antimicrobial Compounds and Methods | CURZA GLOBAL, LLC. | 2023-09-07 | — | — | US | disclosed |
| WO-2021097061-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | CURZA GLOBAL, LLC (US) | 2021-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278987-A1 | Antimicrobial Compounds and Methods | CLPP, RPN2, MPO | CYP1A2 4279/4885CYP11B1 4701/4885CYP11B2 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.